Funds and ETFs Camurus AB

Equities

CAMX

SE0007692850

Pharmaceuticals

Delayed Nasdaq Stockholm 06:59:30 2024-05-08 EDT 5-day change 1st Jan Change
535 SEK +7.82% Intraday chart for Camurus AB +7.39% -0.56%

ETFs positioned on Camurus AB

Name Weight AuM 1st Jan change Investor Rating
0.00% 10 M€ -3.35% -
0.00% 0 M€ +3.45% -
Camurus AB is a Sweden-based research and development based pharmaceutical and biotechnology company with a focus on the development and marketing of specialty medicines, providing patients suffering from severe and chronic disease, such as opioid dependence, pain, cancer, and endocrine diseases. The Company has a diversified research portfolio, which includes products in clinical trials. The Company’s products are based on FluidCrystal formulation technology. FluidCrystal is Company's patent-protected technology platform. Camurus AB is the parent company of the Group, which comprises of legal entities, namely: Camurus Inc, Cubosome Inc, Development AB, Camurus GmbH, Camurus Ltd, Camurus Oy, Camurus AS, Camurus SAS, Camurus Pty Ltd, Camurus S.L, Camurus ApS, Camurus BV and Camurus Austria GmbH.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
535 SEK
Average target price
579.8 SEK
Spread / Average Target
+8.38%
Consensus
  1. Stock Market
  2. Equities
  3. CAMX Stock
  4. Funds and ETFs Camurus AB
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW